EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials

Lawrence A Leiter iD, Frederick J Raal, Gregory G Schwartz iD, Wolfgang Koenig, Kausik K Ray iD, Ulf Landmesser, Jackie Han, Lorena Garcia Conde, R Scott Wright

Diabetes, Obesity and Metabolism · 2024-08 · 26 (8) · 3223-3237

DOI: 10.1111/dom.15650 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.05.2024. Verfasst von Lawrence A Leiter und 8 weiteren Autor:innen. Beteiligte Einrichtung: Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Obesity, Cholesterol, LDL. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG, Basel, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims To conduct a pooled analysis of Phase 3 trials investigating the efficacy and safety of inclisiran across glycaemic and body mass index (BMI) strata. Materials and Methods Participants were randomized 1:1 to receive 300 mg inclisiran sodium or placebo twice yearly, after initial and 3‐month doses up to 18 months, with background oral lipid‐lowering therapy. Analyses were stratified by glycaemic status (normoglycaemia, prediabetes, and diabetes) or BMI (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityCholesterol, LDLHumansFemaleMaleMiddle AgedBlood GlucoseAdultAgedDiabetes Mellitus, Type 2Glycated HemoglobinBody Mass IndexClinical Trials, Phase III as TopicDouble-Blind MethodHypoglycemic AgentsTreatment OutcomeRNA, Small Interfering

Stichwörter der Autor:innen

clinical trialdyslipidaemiaglycaemic controllipid‐lowering therapyrandomized trialtype 2 diabetes

Substanzen

Cholesterol, LDLBlood GlucoseALN-PCSGlycated HemoglobinHypoglycemic AgentsRNA, Small Interfering

Autor:innen und Institutionen

  • Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada.
  • Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
  • DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
  • Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.

ORCID-Profile: Lawrence A Leiter, Gregory G Schwartz, Kausik K Ray

Förderung

  • Novartis Pharma AG, Basel, Switzerland

Zitieren

APA

Leiter, L. A., Raal, F. J., Schwartz, G. G., Koenig, W., Ray, K. K., Landmesser, U., Han, J., Conde, L. G., & Wright, R. S. (2024). Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials. Diabetes, Obesity and Metabolism, 26(8), 3223-3237. https://doi.org/10.1111/dom.15650

Vancouver

Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials. Diabetes, Obesity and Metabolism. 2024;26(8):3223-3237. doi:10.1111/dom.15650

BibTeX
@article{Leiter2024,
  author = {Leiter, Lawrence A and Raal, Frederick J and Schwartz, Gregory G and Koenig, Wolfgang and Ray, Kausik K and Landmesser, Ulf and Han, Jackie and Conde, Lorena Garcia and Wright, R Scott},
  title = {Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {8},
  pages = {3223--3237},
  doi = {10.1111/dom.15650}
}
Kostenlos starten →